FindTrial
Sign In

PHASE II STUDY WITH CETUXIMAB SINGLE AGENT FOLLOWED BY 5-FU, CETUXIMAB AND PELVIC RADIOTHERAPY AS NEO-ADJUVANT TREATMENT FOR OPERABLE, LOCALLY ADVANCED RECTAL CANCER

PHASE II STUDY WITH CETUXIMAB SINGLE AGENT FOLLOWED BY 5-FU, CETUXIMAB AND PELVIC RADIOTHERAPY AS NEO-ADJUVANT TREATMENT FOR OPERABLE, LOCALLY ADVANCED RECTAL CANCER

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-000722-24-IT
Enrollment
Unknown
Registered
2007-08-02
Start date
2005-07-05
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CARCINOMA DEL TRATTO GASTROINTESTINALE, TESTA-COLLO MedDRA version: 6.1 Level: PT Classification code 10038038

Interventions

Trade Name: erbitux Pharmaceutical Form: Solution for infusion INN or Proposed INN: cetuximab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Trade Name: FLU

Sponsors

AZIENDA OSPEDALIERA POLICLINICO DI MODENA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026